5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-alpha)
    Meeting Abstract

    Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Molina, A. M.; Jia, X.; Ginsberg, M. S.; Velasco, S.; Feldman, D. R.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial
    Meeting Abstract

    Montgomery, R. B.; Morris, M. J.; Ryan, C. J.; Stickney, D. R.; Frincke, J. M.; Reading, C. L.; Sarantopoulos, J.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Fluorodeoxyglycose (FDG) PET as an outcome measure for metastatic prostate cancer
    Meeting Abstract

    Morris, M. J.; Fox, J. J.; Dennis, E. R.; Tse, K.; Flatts, E.; Heller, G.; Jia, X.; Schoder, H.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis
    Meeting Abstract

    Mitsiades, N.; Antipin, Y.; Reva, B.; Schultz, N.; Danila, D. C.; Sung, C. C.; Anand, A.; Sander, C.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Meeting Abstract

    Milowsky, M. I.; Trout, A.; Regazzi, A. M.; Garcia-Grossman, I.; Flaherty, A.; Tickoo, S.; Al-Ahmadie, H.; Bajorin, D. F.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial
    Meeting Abstract

    Korhonen, P.; Malangone, E.; Sherman, S.; Casciano, R.; Motzer, R. J.; Baladi, J.; Haas, T.; Zuber, E.; Kay, A. C.; Lebwohl, D. E.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)+
    Meeting Abstract

    Knox, J. J.; Kay, A. C.; Schiff, E.; Hollaender, N.; Rouyrre, N.; Ravaud, A.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Prostate cancer with disseminated intravascular coagulation and excessive fibrinolysis (DIC XFL)
    Meeting Abstract

    Hyman, D. M.; Scher, H. I.; Kampel, L. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Susceptibility loci associated with prostate cancer progression and mortality
    Meeting Abstract

    Gallagher, D. J.; Joseph, V.; Cronin, A.; Vickers, A. J.; Reuter, V. E.; Scher, H. I.; Eastham, J.; Lilja, H.; Kirchhoff, T.; Offit, K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save